Other factors, including IDH1/2, TP53 and EGFR mutation status and 1p19q co-deletion status, which are considered to be associated with glioma progression and patient prognosis, are also significantly different for high- and low-risk groups. Here, IDH1 is linked to central nervous system cancer.